These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. Frebel H; Oxenius A Trends Immunol; 2013 May; 34(5):193-9. PubMed ID: 23333205 [TBL] [Abstract][Full Text] [Related]
43. Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Attanasio J; Wherry EJ Immunity; 2016 May; 44(5):1052-68. PubMed ID: 27192569 [TBL] [Abstract][Full Text] [Related]
44. Chemotherapy and immunotherapy: mapping the road ahead. Cook AM; Lesterhuis WJ; Nowak AK; Lake RA Curr Opin Immunol; 2016 Apr; 39():23-9. PubMed ID: 26724433 [TBL] [Abstract][Full Text] [Related]
45. Inhibitory receptors on lymphocytes: insights from infections. Odorizzi PM; Wherry EJ J Immunol; 2012 Apr; 188(7):2957-65. PubMed ID: 22442493 [TBL] [Abstract][Full Text] [Related]
46. Industry 'road tests' new wave of immune checkpoints. Garber K Nat Biotechnol; 2017 Jun; 35(6):487-488. PubMed ID: 28591107 [No Abstract] [Full Text] [Related]
47. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Okazaki T; Chikuma S; Iwai Y; Fagarasan S; Honjo T Nat Immunol; 2013 Dec; 14(12):1212-8. PubMed ID: 24240160 [TBL] [Abstract][Full Text] [Related]
49. Transcriptional and epigenetic regulation of PD-1 expression. Chi Z; Lu Y; Yang Y; Li B; Lu P Cell Mol Life Sci; 2021 Apr; 78(7):3239-3246. PubMed ID: 33738533 [TBL] [Abstract][Full Text] [Related]
50. Targeting the programmed cell death-1 pathway in rheumatoid arthritis. Sandigursky S; Silverman GJ; Mor A Autoimmun Rev; 2017 Aug; 16(8):767-773. PubMed ID: 28572054 [TBL] [Abstract][Full Text] [Related]
51. Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis. Nagai K Front Med (Lausanne); 2020; 7():584382. PubMed ID: 33251233 [TBL] [Abstract][Full Text] [Related]
52. Inhibitory innate receptors and their potential role in transplantation. Lima K; Ribas GT; Riella LV; Borges TJ Transplant Rev (Orlando); 2023 Jul; 37(3):100776. PubMed ID: 37451057 [TBL] [Abstract][Full Text] [Related]
53. Co-inhibitory receptors, transcription factors and tolerance. Mohammadzadeh A Int Immunopharmacol; 2020 Jul; 84():106572. PubMed ID: 32416452 [TBL] [Abstract][Full Text] [Related]
55. Identification of novel immunosuppressive pathways paves the way for drug discovery. Di Virgilio F; Robson SC Curr Opin Pharmacol; 2009 Aug; 9(4):445-6. PubMed ID: 19625216 [No Abstract] [Full Text] [Related]
56. Current status of cancer immunotherapy. Kono K J Stem Cells Regen Med; 2014; 10(1):8-13. PubMed ID: 25075156 [TBL] [Abstract][Full Text] [Related]
57. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. Ferris RL; Lu B; Kane LP J Immunol; 2014 Aug; 193(4):1525-30. PubMed ID: 25086175 [TBL] [Abstract][Full Text] [Related]
58. Adaptive immunity in cancer immunology and therapeutics. Spurrell EL; Lockley M Ecancermedicalscience; 2014; 8():441. PubMed ID: 25075215 [TBL] [Abstract][Full Text] [Related]
59. Influence of 17-Hydroxyprogesterone, Progesterone and Sex Steroids on Mineralocorticoid Receptor Transactivation in Congenital Adrenal Hyperplasia. Mooij CF; Parajes S; Pijnenburg-Kleizen KJ; Arlt W; Krone N; Claahsen-van der Grinten HL Horm Res Paediatr; 2015 Apr; ():. PubMed ID: 25896481 [TBL] [Abstract][Full Text] [Related]